Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Intern Med. 2006 Mar 21;144(6):438-40.

Viewpoint: limiting prostate cancer screening.

Author information

1
New Mexico Veterans Affairs Health Care System and the Cancer Research and Treatment Center, University of New Mexico School of Medicine, Albuquerque, New Mexico 87108, USA. rhoffman@unm.edu

Abstract

Prostate cancer screening is controversial, and major professional associations offer differing screening guidelines. The author addresses 3 key issues about prostate cancer screening: 1) the prostate-specific antigen (PSA) criteria to recommend a prostate biopsy, 2) the appropriate age to start screening, and 3) the appropriate age to stop screening. The author argues, on the basis of evidence published since 2000, that data supporting the efficacy of PSA screening remain unconvincing. The author recommends that screening should not be expanded to include average-risk men younger than age 50 years or older than age 75 years and that a PSA threshold below 4.0 ng/mL should not be used to trigger biopsy referral.

PMID:
16549856
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center